Navigation Links
GenVec Reports Third Quarter 2009 Financial Results
Date:11/5/2009

e replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, influenza, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to certain of our product candidates being in early stages of development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of thi
'/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Tabletop SEMs are inexpensive ... but have limited performance and capability such as small ... SEMs would normally provide better imaging performance and more ... and have a higher cost of maintenance. The ... between these two types of SEM product, offering competitive ...
(Date:6/18/2013)... 18, 2013 (PRWEB) June 18, 2013 ... attendance system in North America, has introduced AccountLinx ... data and payroll records between ExakTime’s software and ... automates ExakTime software setup and keeps employee databases ... data from a business’ current payroll software, directly ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s ... National AgriScience Teachers Ambassador Academy this week (NATAA) at ... , The NATAA “Ag Academy” is a ... special project of the National FFA Foundation ... . The highly recommended agriscience teachers, who are ...
(Date:6/18/2013)... 18, 2013  regulated information — Global biopharmaceutical company ... today announced the launch of a new Pledge campaign ... The Pledge empowers the millions of ... make a personal commitment to demand more: greater understanding ... team and additional partial-onset seizure control.  More information is ...
Breaking Biology Technology:Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3ExakTime Introduces AccountLinx Plus 2DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... Pioneering Contributions to Personalized Medicine Cited for Honor ... Ruano, M.D., Ph.D., was inducted into the American ... of Fellows today at a ceremony in Washington, ... of this honor are chosen for exceptional leadership ...
... Insurance Coverage of Hepatitis C Patients Is Skewed ... Private Coverage in the General Population, According to ... Feb. 12 Decision Resources, one of the ... pharmaceutical and healthcare issues, finds that hepatitis C ...
... RICHMOND, Va., Feb. 12 Insmed Inc.,(Nasdaq: ... on niche markets with unmet medical needs, announced today ... & Co., Inc. whereby Merck,through an affiliate, will purchase ... the terms of the agreement, Insmed will receive a,total ...
Cached Biology Technology:American Institute for Medical and Biological Engineering Appoints Dr. Gualberto Ruano to College of Fellows 2Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 2Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 3Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million 2Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million 3Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million 4
(Date:6/18/2013)... very large "dead zone" in the Gulf of Mexico ... Chesapeake Bay this year, based on several NOAA-supported forecast ... Louisiana State University, and the Louisiana Universities Marine ... hypoxic "dead" zone will be between 7,286 and 8,561 ... largest recorded. That would range from an area the ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... Association for Molecular Pathology is proud to announce it ... Biology (FASEB) on July 1, 2013. The FASEB Board ... , The 26 constituent societies of FASEB represent ... for the advancement of research and education in biological ... more important now than ever," said Jennifer L. Hunt, ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... Knowing how a living cell works means knowing ... functions of the cell change. Protein phosphorylation, for example, ... to signaling, and even programmed cell death (apoptosis), in ... that has long been intensively studied, not least in ...
... vitamin, but a new research report appearing in the ... is more than that. According to the report, insufficient levels ... innate immune defenses that protect us from infections, neoplasias or ... winter when days are shorter and sunlight is relatively weak, ...
... HAMILTON, ON, April 30, 2012 Urban beach closures ... yet water-testing technology has never been fast enough to keep ... waters. , Now, researchers at McMaster University have developed a ... detect E. coli in recreational water within minutes. ...
Cached Biology News:Molecular spectroscopy tracks living mammalian cells in real time as they differentiate 2Molecular spectroscopy tracks living mammalian cells in real time as they differentiate 3Molecular spectroscopy tracks living mammalian cells in real time as they differentiate 4Molecular spectroscopy tracks living mammalian cells in real time as they differentiate 5Vitamin D supplements may protect against viral infections during the winter 2Researchers develop rapid test strips for bacterial contamination in swimming water 2
... Rat adult normal paraffin tissue array ... or proteins of interest in extensive ... Rat brain, heart, kidney, liver, ... are arrayed on positively charged glass ...
Rat Normal Multiple Tissue Array 1 slide...
... DeStreak Reagent, 1 ml. ... 2-D gels by preventing streaking.Eliminates ... oxidation of proteins.Stabilizes proteins throughout ... simplified, well-resolved protein patterns.Ideal for ...
Request Info...
Biology Products: